Inactive Instrument

Kadmon Holdings, Inc.

KDMN

US48283N1063

Kadmon Holdings, Inc.(NasdaqGS:KDMN) dropped from NASDAQ Biotechnology Index

November 08, 2021 at 12:00 am EST

Kadmon Holdings, Inc. has been removed from NASDAQ Biotech Index.

Latest news about Kadmon Holdings, Inc.

Sanofi in $1 bln deal to buy U.S.-based Amunix Pharma	21-12-21	RE
Kadmon Holdings, Inc.(NasdaqGS:KDMN) dropped from S&P Global BMI Index	21-11-10	CI
Kadmon Holdings, Inc.(NasdaqGS:KDMN) dropped from S&P TMI Index	21-11-10	CI
Kadmon Holdings, Inc.(NasdaqGS:KDMN) dropped from S&P Biotechnology Select Industry Index	21-11-10	CI
Sanofi Closes on Kadmon Acquisition	21-11-09	MT
Kadmon Holdings, Inc.(NasdaqGS:KDMN) dropped from NASDAQ Composite Index	21-11-09	CI
Sanofi completed the acquisition of Kadmon Holdings, Inc..	21-11-08	CI
Kadmon Holdings, Inc.(NasdaqGS:KDMN) dropped from NASDAQ Biotechnology Index	21-11-08	CI
Kadmon Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-04	CI
Earnings Flash (KDMN) KADMON HOLDINGS Reports Q3 Revenue $14.7M	21-11-04	MT
Kadmon : Health Care Stocks Edging Higher At Close	21-10-21	MT
Sector Update: Health Care	21-10-21	MT
Kadmon : Announces Expiration of HSR Waiting Period in Sanofi Deal	21-10-21	MT
North American Morning Briefing : Stock Futures -3-	21-09-15	DJ
KADMON : Mizuho Securities Downgrades Kadmon Holdings to Neutral from Buy, Adjusts Price Target to $9.50 from $13	21-09-14	MT
KADMON : UBS Downgrades Kadmon Holdings to Neutral From Buy, Adjusts PT to $9.50 From $9	21-09-10	MT
North American Morning Briefing : Stock Futures -3-	21-09-10	DJ
KADMON : Oppenheimer Suspends Rating for Kadmon Holdings Following Sanofi Merger	21-09-09	MT
KADMON : Jefferies Downgrades Kadmon Holdings to Hold from Buy, Adjusts Price Target to $9.50 from $10	21-09-09	MT
ADRs End Lower; Nio, Sanofi Among Companies Actively Trading	21-09-08	DJ
Health Care Flat On Defensive Bias -- Health Care Roundup	21-09-08	DJ
Alector : Health Care Stocks Edging Lower Just Ahead of Wednesday Close	21-09-08	MT
Flora Growth : Health Care Stocks Fighting to Overcome Market Downdrafts	21-09-08	MT
Top Midday Gainers	21-09-08	MT
Stoxx Europe 600 : European Stocks Close Lower Amid Economic Growth Concerns, Rising COVID-19 Cases	21-09-08	MT

Kadmon Holdings, Inc. is a biopharmaceutical company, which is engaged in discovering, developing, and delivering therapies for unmet medical needs. The Company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. It is developing oral small molecule inhibitors of Rho-associated coiled-coil kinase (ROCK) to treat immune and fibrotic diseases. Its advanced product candidate, Belumosudil (KD025) is an orally administered, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2). The Company has a biologics research platform focused on the development of immuno-oncology therapeutics, specifically, IL-15-containing fusion proteins for the treatment of cancer. Its advanced candidate from the biologics platform, KD033, is an anti-PD-L1/IL-15 fusion protein designed to stimulate an immune response directed to the tumor microenvironment. IL-15 is a cytokine that expands key tumor-fighting immune cell types.

Sector

Pharmaceuticals

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
CSL LIMITED	-2.86%	87.31B
SAMSUNG BIOLOGICS CO.,LTD.	+2.63%	40.86B
BIOGEN INC.	-22.91%	29.36B
UCB	+58.56%	24.49B
BIOMARIN PHARMACEUTICAL INC.	-13.47%	17.31B
INCYTE CORPORATION	-18.92%	11.62B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-15.61%	11.31B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-44.02%	11.26B
SWEDISH ORPHAN BIOVITRUM AB	+5.17%	8.31B

Biopharmaceuticals